Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2022-11, Vol.140 (Supplement 1), p.7028-7029
Hauptverfasser: Awan, Farrukh T., Deshpande, Gaurav A., Le, Trong Kim, Garrison, Sean, Tiwana, Simran K., Priyadarshini, Masoom
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7029
container_issue Supplement 1
container_start_page 7028
container_title Blood
container_volume 140
creator Awan, Farrukh T.
Deshpande, Gaurav A.
Le, Trong Kim
Garrison, Sean
Tiwana, Simran K.
Priyadarshini, Masoom
description
doi_str_mv 10.1182/blood-2022-159195
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_159195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000649712204678X</els_id><sourcerecordid>S000649712204678X</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1375-d25e48edef106503d8032d6716f0ac5d58f11f947e80f8c4aa94a6b66187f4493</originalsourceid><addsrcrecordid>eNp9kc1u1DAURgMqEkPhAdjd5WSRju38i1UnglI1UkdtUJeRx74hhiQe2Z5C3h6ngyp105Wv5e_Yx_qC4DMlF5QWbLMftJYRI4xFNC1pmb4NVjRlRUQII2fBihCSRUmZ0_fBB2t_EUKTmKWrN3CHfIgetBkkNAa5G3FysG7-hrDjzqGZLPBJQjWoSQk-wO3RCT2ihctRTz-XkPKEhfXO2RD-KNdD1Rvtw1DP46HXYnbLjMffOCq-uR_5MLw8eppHDuuqrjf3dR3CQ6-9mED1iBK48zS3DhjsjNIGajX593UHTY-GH2a4nsRwlMrrbM3R6Qma2WjrU3CjJm7RB3q1V86z621zo8LlSxu_20YVPtt4A_YiWdVMhR-Ddx0fLH76v54HP759barvUX17dV1d1pGgcZ5GkqWYFCixoyRLSSwLEjOZ5TTrCBepTIuO0q5McixIV4iE8zLh2T7LaJF3SVLG5wE93Su8ujXYtQejRm7mlpJ2qbh9qrhdKm5PFXvmy4lBL_ao0LRW-DYESmVQuFZq9Qr9D8FLsCA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Awan, Farrukh T. ; Deshpande, Gaurav A. ; Le, Trong Kim ; Garrison, Sean ; Tiwana, Simran K. ; Priyadarshini, Masoom</creator><creatorcontrib>Awan, Farrukh T. ; Deshpande, Gaurav A. ; Le, Trong Kim ; Garrison, Sean ; Tiwana, Simran K. ; Priyadarshini, Masoom</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-159195</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.7028-7029</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Awan, Farrukh T.</creatorcontrib><creatorcontrib>Deshpande, Gaurav A.</creatorcontrib><creatorcontrib>Le, Trong Kim</creatorcontrib><creatorcontrib>Garrison, Sean</creatorcontrib><creatorcontrib>Tiwana, Simran K.</creatorcontrib><creatorcontrib>Priyadarshini, Masoom</creatorcontrib><title>Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAURgMqEkPhAdjd5WSRju38i1UnglI1UkdtUJeRx74hhiQe2Z5C3h6ngyp105Wv5e_Yx_qC4DMlF5QWbLMftJYRI4xFNC1pmb4NVjRlRUQII2fBihCSRUmZ0_fBB2t_EUKTmKWrN3CHfIgetBkkNAa5G3FysG7-hrDjzqGZLPBJQjWoSQk-wO3RCT2ihctRTz-XkPKEhfXO2RD-KNdD1Rvtw1DP46HXYnbLjMffOCq-uR_5MLw8eppHDuuqrjf3dR3CQ6-9mED1iBK48zS3DhjsjNIGajX593UHTY-GH2a4nsRwlMrrbM3R6Qma2WjrU3CjJm7RB3q1V86z621zo8LlSxu_20YVPtt4A_YiWdVMhR-Ddx0fLH76v54HP759barvUX17dV1d1pGgcZ5GkqWYFCixoyRLSSwLEjOZ5TTrCBepTIuO0q5McixIV4iE8zLh2T7LaJF3SVLG5wE93Su8ujXYtQejRm7mlpJ2qbh9qrhdKm5PFXvmy4lBL_ao0LRW-DYESmVQuFZq9Qr9D8FLsCA</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Awan, Farrukh T.</creator><creator>Deshpande, Gaurav A.</creator><creator>Le, Trong Kim</creator><creator>Garrison, Sean</creator><creator>Tiwana, Simran K.</creator><creator>Priyadarshini, Masoom</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)</title><author>Awan, Farrukh T. ; Deshpande, Gaurav A. ; Le, Trong Kim ; Garrison, Sean ; Tiwana, Simran K. ; Priyadarshini, Masoom</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1375-d25e48edef106503d8032d6716f0ac5d58f11f947e80f8c4aa94a6b66187f4493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Awan, Farrukh T.</creatorcontrib><creatorcontrib>Deshpande, Gaurav A.</creatorcontrib><creatorcontrib>Le, Trong Kim</creatorcontrib><creatorcontrib>Garrison, Sean</creatorcontrib><creatorcontrib>Tiwana, Simran K.</creatorcontrib><creatorcontrib>Priyadarshini, Masoom</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Awan, Farrukh T.</au><au>Deshpande, Gaurav A.</au><au>Le, Trong Kim</au><au>Garrison, Sean</au><au>Tiwana, Simran K.</au><au>Priyadarshini, Masoom</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>7028</spage><epage>7029</epage><pages>7028-7029</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-159195</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-11, Vol.140 (Supplement 1), p.7028-7029
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2022_159195
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A34%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-World%20Treatment%20(Tx)%20Patterns%20and%20Clinical%20Outcomes%20Among%20Patients%20(Pts)%20with%20Chronic%20Lymphocytic%20Leukemia/Small%20Lymphocytic%20Lymphoma%20(CLL/SLL)%20Who%20Received%20at%20Least%202%20Prior%20Lines%20of%20Therapy%20Including%20Bruton%20Tyrosine%20Kinase%20Inhibitor%20(BTKi)%20and/or%20B-Cell%20Lymphoma%202%20Inhibitor%20(BCL2i)&rft.jtitle=Blood&rft.au=Awan,%20Farrukh%20T.&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=7028&rft.epage=7029&rft.pages=7028-7029&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-159195&rft_dat=%3Celsevier_cross%3ES000649712204678X%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S000649712204678X&rfr_iscdi=true